CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-11). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 231 · Search date 2026-07-11 · Methodology v0.6

Red clover isoflavones,
does it really help with Relief of menopausal hot flashes and night sweats?

30-Second Summary
C
Evidence Grade C · 48 · Safety caution
Hot-flash reduction varies by formulation and the average effect is not large
What the
research shows
The large 252-person ICE trial and Cochrane pooling found no benefit over placebo for red clover isoflavones, whereas a 2026 meta-analysis reported a modest reduction in hot-flash frequency (SMD −0.446). The conflict between a null large trial and earlier synthesis and a modestly positive recent meta-analysis supports C.
What the
ads claim
Advertisements use phrases such as 'plant estrogen,' 'solves heat and cold sweats,' and 'hormone balance.' Actual results differ by formulation and, even when an average effect is present, represent a modest change in hot-flash frequency.
*

Useful facts when choosing a product

  • Trial doses ranged widely, from about 37.1 to 160 mg/day of total isoflavones.
  • Promensil and Rimostil are standardized formulations with different isoflavone amounts and compositions.
  • Hot-flash diaries and menopause symptom scales were the main endpoints.
  • Short-term adverse events were similar to placebo, but long-term safety and safety in hormone-sensitive conditions are not adequately established.
Gap Measurement · Verdict 231 · C 48
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The Tice 2003 ICE trial assigned 252 women to Promensil 82 mg, Rimostil 57 mg, or placebo for 12 weeks and found similar reductions in hot flashes. In the Lethaby 2013 Cochrane review, the difference across five Promensil trials was nonsignificant. Jiang 2026 reported a small-to-moderate effect across nine RCTs, but doses ranged from 37.1 to 160 mg and durations from 12 weeks to 12 months, with differing formulations.

02

Why this is classified as C (48)

The large 252-person ICE trial and Cochrane pooling were null, while the 2026 meta-analysis was modestly positive at SMD −0.446. The direction does not converge and formulations and doses are heterogeneous, resulting in C with 48 points.

Counterpoint. A small effect remains possible for particular higher-dose standardized formulations and people with frequent symptoms. This judgment applies to the product class on average.

Rejudgment record. Reassessment (cross-check reflected) — A null large 252-person ICE trial and Cochrane pooling conflict with a modestly positive 2026 meta-analysis (SMD −0.446), supporting C

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Tice JA et al. 2003Multicenter randomized double-blind placebo-controlled trial252Linked to Novogen products and supportDaily hot-flash frequency and quality of life over 12 weeksReductions were similar with Promensil, Rimostil, and placebo, with no clinically important difference.Decisive
Lethaby A et al. 2013Cochrane systematic review5Independent academic reviewHot-flash frequency and menopausal vasomotor symptomsPromensil versus placebo was nonsignificant, MD -0.93/day (95% CI -1.95 to 0.10).Key
Jiang W, Wu K. 2026GRADE-assessed systematic review and meta-analysis9No conflicts reportedHot-flash frequency and severityReported a small-to-moderate reduction in frequency, SMD -0.446 (95% CI -0.807 to -0.084).Key
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-11).

Tice JA, Ettinger B, Ensrud K, Wallace R, Blackwell T, Cummings SR. 2003. Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA. 2003;290(2):207-214. PMID: 12851275. DOI: 10.1001/jama.290.2.207.
checked
Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. 2013. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev. 2013;(12):CD001395. PMID: 24323914. DOI: 10.1002/14651858.CD001395.pub4.
checked
Jiang W, Wu K. 2026. The effectiveness of red clover on hot-flash in menopausal women: a GRADE-assessed systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2026;324:115226. PMID: 42269521. DOI: 10.1016/j.ejogrb.2026.115226.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-11 · Corrections: none

Cite this verdict

Red clover isoflavones x relief of menopausal hot flashes and night sweats Evidence Grade C card
[Chamgap] Red clover isoflavones x relief of menopausal hot flashes and night sweats — Evidence Grade C·48. 3 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/womens/red-clover-hot-flashes-night-sweats/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.